Results 131 to 140 of about 18,601 (174)

Ocular Manifestations of Chronic Infantile Neurological Cutaneous and Articular Syndrome: A Case Report. [PDF]

Korean J Ophthalmol
Kim H, Woo SJ.
europepmc   +1 more source

Case Report: Hyperinflammatory toxicities after Epstein-Barr virus-associated post-transplant lymphoproliferative disorder and hemophagocytic lymphohistiocytosis in a pediatric kidney transplant recipient. [PDF]

Front Immunol
Ussowicz M, Jarmużek W, Rutynowska-Pronicka O, Śliwińska A, Bogacz A, Zielińska M, Litwin M, Dembowska-Bagińska B.   +7 more
europepmc   +1 more source

Case Report: Treatment of refractory lung disease in systemic juvenile idiopathic arthritis with cyclophosphamide and rituximab combination therapy. [PDF]

Front Immunol
Freeman WJ, Rife EC, Cron RQ.
europepmc   +1 more source

Comparative Efficacy and Safety of Anakinra and Canakinumab in Patients With VEXAS Syndrome: An International Multicenter Study. [PDF]

Arthritis Rheumatol
Eviatar T, Capelusnik D, Campochiaro C, Lacombe V, Jachiet V, Zisapel M, Sagy I, Tayer-Shifman OE, Ozeri D, Kivity S, Tomelleri A, Terrier B, Peleg H, Comont T, Sacre K, Woaye-Hune P, Arnaud L, Lazaro E, Grobost V, Lifermann F, Samson M, Ardois S, Garnier A, Maria A, Cantagrel A, Meyer A, Bouaziz JD, Heiblig M, Dagna L, Diral E, Kosmider O, Elkayam O, Hadjadj J, Georgin-Lavialle S, Fain O, Mekinian A.   +35 more
europepmc   +1 more source

Anakinra for infants under six months with Kawasaki disease and coronary artery lesions: a multicenter case series and literature review. [PDF]

Pediatr Rheumatol Online J
Inguscio G, Romano S, Fabi M, Gargiullo L, Marchesi A, Maggio MC, Mastrolia MV, Calabri GB, Simonini G, Giani T.   +9 more
europepmc   +1 more source

Pericarditis in Patients with Autoimmune Disease: Insights into Prevalence and Optimal Management. [PDF]

Methodist Debakey Cardiovasc J
Fakikh Y, Kazzaz S, Malahfji M.
europepmc   +1 more source

Efficacy of anakinra in reducing progression to organ dysfunction in patients with pneumonia (INSPIRE): a randomised, double-blind, placebo-controlled, phase IIa trial. [PDF]

Lancet Reg Health Eur
Tavoulareas G, Kontakou-Zoniou O, Antonakos N, Tasouli E, Adamis G, Kakavoulis N, Michelakis E, Skopelitis I, Dakou K, Psarrakis C, Koufargyris P, Astriti M, Sympardi S, Giamarellos-Bourboulis EJ.   +13 more
europepmc   +1 more source

Interleukin-1 receptor antagonist autoantibodies in Still's disease: Mechanistic insights and laboratory testing. [PDF]

World J Methodol
Bouayad A.
europepmc   +1 more source

A Diagnosis of Exclusion: Unraveling Adult-Onset Still's Disease. [PDF]

Cureus
Aswani A, Akinyooye OA, Gudger M, Barreda-Velit C, Abreu O, Ferguson S, Thompson C.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Anakinra

BioDrugs, 2002
Anakinra, a recombinant human interleukin-1 (IL-1) receptor antagonist, is the first biological agent approved to block the pro-inflammatory effects of IL-1 in patients with rheumatoid arthritis. In a double-blind, randomised trial in 472 patients with active, severe or very severe rheumatoid arthritis, recipients of subcutaneous anakinra 150 mg/day ...
Risto S, Cvetkovic, Gillian, Keating
openaire   +2 more sources